Clinical Trial Update: National Acalabrutinib Observational Study

View source ↗

Summary

A national observational study of acalabrutinib in chronic lymphocytic leukemia is updated and currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Lymphocytic Leukemia | Status: ACTIVE_NOT_RECRUITING